Stephen Doberstein

Dr. Stephen K.
Doberstein is an Independent Director at Invea Therapeutics, Inc., an Independent Director at Forte Biosciences, Inc. and a Principal at Kahiliholo Consulting LLC.
He is on the Board of Directors at Invea Therapeutics, Inc. and Forte Biosciences, Inc. Dr. Doberstein was previously employed as an Independent Director by Dicerna Pharmaceuticals, Inc., a Chief Scientific Fellow & Senior Vice President by Nektar Therapeutics, a Vice President-Research by XOMA Royalty Corp., a Vice President-Research by Five Prime Therapeutics, Inc., a Vice President-Research by Xencor, Inc., a Director-Pharmaceutical Target Research by Exelixis, Inc., and an Engineer by EIDP, Inc. He also served on the board at Parmedics, Inc. He received his undergraduate degree from the University of Delaware and a doctorate degree from The Johns Hopkins University School of Medicine.